- Home
- DSGN vs TRDA Comparison
DSGN vs TRDA Comparison
Compare DSGN & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- TRDA
- Stock Information
- Founded
- DSGN 2017
- TRDA 2016
- Country
- DSGN United States
- TRDA United States
- Employees
- DSGN N/A
- TRDA N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- TRDA Health Care
- Exchange
- DSGN Nasdaq
- TRDA Nasdaq
- Market Cap
- DSGN 208.9M
- TRDA 233.5M
- IPO Year
- DSGN 2021
- TRDA 2021
- Fundamental
- Price
- DSGN $6.03
- TRDA $5.28
- Analyst Decision
- DSGN
- TRDA Strong Buy
- Analyst Count
- DSGN 0
- TRDA 3
- Target Price
- DSGN N/A
- TRDA $25.67
- AVG Volume (30 Days)
- DSGN 171.5K
- TRDA 234.2K
- Earning Date
- DSGN 11-06-2025
- TRDA 11-04-2025
- Dividend Yield
- DSGN N/A
- TRDA N/A
- EPS Growth
- DSGN N/A
- TRDA N/A
- EPS
- DSGN N/A
- TRDA N/A
- Revenue
- DSGN N/A
- TRDA $79,476,000.00
- Revenue This Year
- DSGN N/A
- TRDA N/A
- Revenue Next Year
- DSGN N/A
- TRDA N/A
- P/E Ratio
- DSGN N/A
- TRDA N/A
- Revenue Growth
- DSGN N/A
- TRDA N/A
- 52 Week Low
- DSGN $2.60
- TRDA $4.93
- 52 Week High
- DSGN $7.77
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- DSGN 58.00
- TRDA 42.86
- Support Level
- DSGN $5.65
- TRDA $5.08
- Resistance Level
- DSGN $6.65
- TRDA $5.53
- Average True Range (ATR)
- DSGN 0.51
- TRDA 0.26
- MACD
- DSGN -0.00
- TRDA 0.02
- Stochastic Oscillator
- DSGN 64.27
- TRDA 18.87
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.